Mentice AB (publ) (MNTC.ST)
SEK 20.4
(-1.45%)
SEK 20.4
(-1.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.81 Million SEK | 90.81% |
| 2022 | -30.66 Million SEK | -5.05% |
| 2021 | -29.19 Million SEK | -122.97% |
| 2020 | -13.09 Million SEK | 36.45% |
| 2019 | -20.6 Million SEK | -202.24% |
| 2018 | 20.14 Million SEK | 225.91% |
| 2017 | 6.18 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 17.24 Million SEK | 169.98% |
| 2024 Q1 | -24.64 Million SEK | -772.87% |
| 2023 Q2 | 1.47 Million SEK | 199.33% |
| 2023 Q1 | -1.48 Million SEK | -169.2% |
| 2023 FY | -2.81 Million SEK | 90.81% |
| 2023 Q4 | -2.82 Million SEK | -17743.75% |
| 2023 Q3 | 16 Thousand SEK | -98.91% |
| 2022 Q2 | -17.63 Million SEK | -137.58% |
| 2022 Q1 | -7.42 Million SEK | -76.85% |
| 2022 FY | -30.66 Million SEK | -5.05% |
| 2022 Q4 | 2.14 Million SEK | 127.67% |
| 2022 Q3 | -7.74 Million SEK | 56.08% |
| 2021 Q1 | -12.39 Million SEK | -472.12% |
| 2021 Q2 | -5.36 Million SEK | 56.75% |
| 2021 Q4 | -4.19 Million SEK | 41.94% |
| 2021 Q3 | -7.23 Million SEK | -34.83% |
| 2021 FY | -29.19 Million SEK | -122.97% |
| 2020 Q4 | 3.33 Million SEK | 1080.0% |
| 2020 Q3 | -340 Thousand SEK | 96.94% |
| 2020 Q2 | -11.1 Million SEK | -123.17% |
| 2020 Q1 | -4.97 Million SEK | -164.22% |
| 2020 FY | -13.09 Million SEK | 36.45% |
| 2019 FY | -20.6 Million SEK | -202.24% |
| 2019 Q4 | 7.75 Million SEK | 186.36% |
| 2019 Q3 | -8.97 Million SEK | 17.17% |
| 2019 Q2 | -10.83 Million SEK | -26.83% |
| 2019 Q1 | -8.54 Million SEK | -130.76% |
| 2018 Q2 | -4.5 Million SEK | -61.12% |
| 2018 Q3 | -332 Thousand SEK | 92.62% |
| 2018 Q4 | 27.77 Million SEK | 8465.36% |
| 2018 FY | 20.14 Million SEK | 225.91% |
| 2018 Q1 | -2.79 Million SEK | 0.0% |
| 2017 FY | 6.18 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 96.381% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 102.722% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 102.722% |
| Arcoma AB | 2.56 Million SEK | 209.867% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 97.964% |
| BICO Group AB (publ) | -835.7 Million SEK | 99.663% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 111.278% |
| CellaVision AB (publ) | 130.3 Million SEK | 102.162% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 96.47% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 90.348% |
| C-Rad AB (publ) | 35.52 Million SEK | 107.929% |
| Duearity AB (publ) | -26.19 Million SEK | 89.244% |
| Dignitana AB (publ) | -17.36 Million SEK | 83.776% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 97.028% |
| Getinge AB (publ) | 2.41 Billion SEK | 100.117% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 95.856% |
| Iconovo AB (publ) | -45.89 Million SEK | 93.862% |
| Integrum AB (publ) | 4.03 Million SEK | 169.858% |
| Luxbright AB (publ) | -25.37 Million SEK | 88.899% |
| OssDsign AB (publ) | -130.49 Million SEK | 97.841% |
| Paxman AB (publ) | 8.33 Million SEK | 133.818% |
| Promimic AB (publ) | -9.22 Million SEK | 69.453% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 98.239% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 94.932% |
| ScandiDos AB (publ) | -14.64 Million SEK | 80.767% |
| Sectra AB (publ) | 428.38 Million SEK | 100.658% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 95.274% |
| Senzime AB (publ) | -134.14 Million SEK | 97.9% |
| SpectraCure AB (publ) | -20.44 Million SEK | 86.219% |
| Stille AB | 26.64 Million SEK | 110.572% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.927% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 103.068% |